---
title: "Alcon Q2 FY26 operating income drops 96% to $11 million; net sales rise 8% to $2.78 billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295449359.md"
description: "Alcon reported Q2 FY26 net sales of $2.78 billion, up 8%, but operating income plummeted 96% to $11 million due to a $505 million impairment from discontinuing PowerVision programs, which also drove R&D expenses up 171%. Consequently, net income turned from profit to zero. Vision Care and Surgical segments saw contributions rise 36% and 4% respectively. First-half net sales grew 9% to $5.47 billion, while operating income fell 58%."
datetime: "2026-08-10T20:46:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295449359.md)
  - [en](https://longbridge.com/en/news/295449359.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295449359.md)
generator: "portal-rs"
---

# Alcon Q2 FY26 operating income drops 96% to $11 million; net sales rise 8% to $2.78 billion

-   Alcon net sales rose 8% to $2.78 billion in Q2 2026. \* Operating income plunged 96% to $11 million, turning net income attributable to shareholders to no profit from a year earlier. \* Research and development expense jumped 171% to $663 million on a $505 million impairment tied to discontinuing the PowerVision programs. \* Vision Care segment contribution climbed 36% to $283 million, while Surgical segment contribution rose 4% to $392 million. \* First-half net sales increased 9% to $5.47 billion, while operating income fell 58% to $303 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alcon AG published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ALC.US](https://longbridge.com/en/quote/ALC.US.md)

## Related News & Research

- [ALC: Record revenue, strong ARR growth, and strategic acquisition drive positive FY 2027 outlook](https://longbridge.com/en/news/296293743.md)
- [Eye care company Alcon raises margin outlook, shares jump](https://longbridge.com/en/news/295501993.md)
- [ALC: Strong sales growth offset by a major impairment charge led to sharply lower earnings](https://longbridge.com/en/news/295486138.md)
- [EyePoint says Phase 3 LUGANO trial of DURAVYU in wet AMD misses primary endpoint](https://longbridge.com/en/news/296094908.md)
- [Surgical Science Sweden (OM:SUS) Stock Rich Margins Meet A Durability Question](https://longbridge.com/en/news/296529240.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**